The apolipoprotein B R3531C mutation: Characteristics of 24 subjects from 9 kindreds

Journal of Lipid Research

Volumn 40, Issue 2, 1999, Pages 318-327

  Pullinger, Clive R ^a   Gaffney, Dairena ^b   Gutierrez, Monica M ^c   Malloy, Mary J ^a   Schumaker, Verne N ^c   Packard, Chris J ^b   Kane, John P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apolipoprotein B; Atherosclerosis; Genetic mutation; Haplotypes; Hypercholesterolemia

Indexed keywords

APOLIPOPROTEIN B; DNA; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DENATURING GRADIENT GEL ELECTROPHORESIS; GENE; GENE MUTATION; HUMAN; HUMAN CELL; LIGHT SCATTERING; MAJOR CLINICAL STUDY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR BINDING; ADOLESCENT; ADULT; AGED; ALLELE; BLOOD; CELL STRAIN U937; CHILD; CYTOLOGY; EXON; FEMALE; FIBROBLAST; GENETIC POLYMORPHISM; GENETICS; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PEDIGREE; POINT MUTATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; RADIOASSAY; SKIN;

ADOLESCENT; ADULT; AGED; ALLELES; APOLIPOPROTEINS B; CHILD; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EXONS; FEMALE; FIBROBLASTS; HUMANS; LIPIDS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PEDIGREE; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RADIOLIGAND ASSAY; RECEPTORS, LDL; SKIN; U937 CELLS;

EID: 0032908140     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Kane, J. P., and R. J. Havel. 1995. Disorders of the biogenesis and secretion of lipoproteins containing the B-apolipoproteins. In The Metabolic and Molecular Bases of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill, New York. 1853-1885.
2. Soria, L. F., E. H. Ludwig, H. R. G. Clarke, G. L. Vega, S. M. Grundy, and B. J. McCarthy. 1989. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc. Natl. Acad. Sci. USA. 86: 587-591.
3. Pullinger, C. R., L. K. Hennessy, J. A. Love, P. H. Frost, C. M. Mendel, W. Liu, M. J. Malloy, and J. P. Kane. 1993. Familial ligand-defective apolipoprotein B: identification of a new mutation that decreases LDL receptor binding affinity. Circulation. 88: I-322.
4. Pullinger, C. R., L. K. Hennessy, J. E. Chatterton, W. Q. Liu, J. A. Love, C. M. Mendel, P. H. Frost, M. J. Malloy, V. N. Schumaker, and J. P. Kane. 1995. Familial ligand-defective apolipoprotein B: identification of a new mutation that decreases LDL receptor binding affinity. J. Clin. Invest. 95: 1225-1234.
5. Gaffney, D., J. M. Reid, I. M. Cameron, K. Vass, M. J. Caslake, J. Shepherd, and C. J. Packard. 1995. Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 15: 1025-1029.
6. Young, S. G., S. J. Bertics, L. K. Curtiss, D. C. Casal, and J. L. Witztum. 1986. Monoclonal antibody MB19 detects genetic polymorphism in human apolipoprotein B. Proc. Natl. Acad. Sci. USA. 83: 1101-1105.
7. Young, S. G., and S. T. Hubl. 1989. An ApaLI restriction site polymorphism is associated with the MB19 polymorphism in apolipoprotein B. J. Lipid Res. 30: 443-449.
8. Ma, Y., X. Wang, R. Bütler, and V. N. Schumaker. 1989. Bsp 12861 restriction fragment length polymorphism detects Ag(c/g) locus of human apolipoprotein B in all 17 persons studied. Arteriosclerosis. 9: 242-246.
9. Young, S., S. Bertics, T. Scott, B. Dubois, W. Beltz, L. Curtiss, and J. Witztum. 1987. Apolipoprotein B allotypes MB19(1) and MB19(2) in subjects with coronary artery disease and hypercholesterolemia. Arteriosclerosis. 7: 61-65.
10. Young, S. G., S. J. Bertics, L. K. Curtiss, B. W. Dubois, and J. L. Witztum. 1987. Genetic analysis of a kindred with familial hypobetalipoproteinemia. J. Clin. Invest. 79: 1842-1851.
11. Gavish, D., E. A. Brinton, and J. L. Breslow. 1989. Heritable allele-specific differences in amounts of apoB and low-density lipoproteins in plasma. Science. 244: 72-76.
12. Arnold, K. S., M. E. Balestra, R. M. Krauss, L. K. Curtiss, S. G. Young, and T. L. Innerarity. 1994. Isolation of allele-specific, receptor-binding-defective low density lipoproteins from familial defective apolipoprotein B-100 subjects. J. Lipid Res. 35: 1469-1476.
13. Friedl, W., E. Ludwig, M. Balestra, K. Arnold, B. Paulweber, F. Sandhofer, B. McCarthy, and T. Innerarity. 1991. Apolipoprotein B gene mutations in Austrian subjects with heart disease and their kindred. Arterioscler. Thromb. 11: 371-378.
14. Chatterton, J. E., P. Schlapfer, E. Butler, M. M. Gutierrez, D. L. Puppione, C. R. Pullinger, J. P. Kane, L. K. Curtiss, and V. N. Schumaker. 1995. Identification of apolipoprotein B-100 polymorphisms that affect low density lipoprotein metabolism: description of a new approach involving monoclonal antibodies and dynamic light scattering. Biochemistry. 34: 9571-9580.
15. Myers, R. M., T. Maniatis, and L. S. Lerman. 1987. Detection and localization of single base changes by denaturing gradient gel electrophoresis. Methods Enzymol. 155: 501-527.
16. Mendel, C. M. 1994. A novel assay for comparing affinity constants of ligands with small differences in affinity: application to low-density lipoproteins. Anal. Biochem. 216: 328-334.
17. Karlsen, F., H. B. Steen, and J. M. Nesland. 1995. SYBR green I DNA staining increases the detection sensitivity of viruses by polymerase chain reaction. J. Virol. Methods. 55: 153-156.
18. Zysow, B. R., C. R. Pullinger, L. K. Hennessy, R. V. Farese, M. Ghassemzadeh, and J. P. Kane. 1994. The apolipoprotein C-II variant apoC-II(Lys19→Thr) is not associated with dyslipidemia in an affected kindred. Clin. Genet. 45: 292-297.
19. Curtiss, L. K., and T. S. Edgington. 1982. Immunochemical heterogeneity of human plasma apolipoprotein B. I. Apolipoprotein B binding of mouse hybridoma antibodies. J. Biol. Chem. 257: 15213-15221.
20. Young, S. G., J. L. Witztum, D. C. Casal, L. K. Curtiss, and S. Bernstein. 1986. Conservation of the low density lipoprotein receptor-binding domain of apoprotein B: demonstration by a new monoclonal antibody, MB47. Arteriosclerosis. 6: 178-188.
21. Goldstein, J. L., S. K. Basu, and M. S. Brown. 1983. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol. 98: 241-260.
22. Ludwig, E. H., W. Friedl, and B. J. McCarthy. 1989. High-resolution analysis of a hypervariable region in the human apolipoprotein B gene. Am. J. Hum. Genet. 45: 458-464.
23. Innerarity, T. L., R. W. Mahley, K. H. Weisgraber, T. P. Bersot, R. M. Krauss, G. L. Vega, S. M. Grundy, W. Friedl, J. Davignon, and B. J. McCarthy. 1990. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J. Lipid Res. 31: 1337-1349.
24. Dianzani, I., C. Camaschella, A. Ponzone, and R. G. Cotton. 1993. Dilemmas and progress in mutation detection. Trends Genet. 9: 403-405.
25. Lipid Research Clinics' Program. 1980. Population Studies Data Book: Vol. I, The Prevalence Study. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health (NIH publication number 80-1527), Washington, DC.
26. Frostegard, J., A. Hainsten, M. Gidlund, and J. Nilsson. 1990. Low density lipoprotein-induced growth of U937 cells: a novel method to determine the receptor binding of low density lipoprotein. J. Lipid Res. 31: 37-44.
27. Schewe, C. K., H. Schuster, S. Hailer, G. Wolfram, C. Keller, and N. Zollner. 1994. Identification of defective binding of low density lipoprotein by the U937 proliferation assay in German patients with familial defective apolipoprotein B-100. Eur. J. Clin. Invest. 24: 36-41.
28. Wieringa, G., K. Tebbutt, G. Burrows, J. Rafferty, D. Gaffney, and E. Gowland. 1996. Idendification of a patient homozygous for familial defective apolipoprotein B (FDB). Proc. Int. Congress Clin. Chem. - XVI.
29. Ludwig, E. H., P. N. Hopkins, A. Allen, L. L. Wu, R. R. Williams, J. L. Anderson, R. H. Ward, J-M. Lalouel, and T. L. Innerarity. 1997. Association of genetic variations in apolipoprotein B with hypercholesterolemia, coronary artery disease, and receptor binding of low density lipoproteins. J. Lipid Res. 38: 1361-1373.
30. Wenham, P. R., B. G. Henderson, M. D. Penney, P. Ashby, P. W. H. Rae, and S. W. Walker. 1997. Familial ligand-defective apolipoprotein B-100: detection, biochemical features and haplotype analysis of the R3531C mutation in the UK. Atherosclerosis. 129: 185-192.
31. Rabes, J. P., M. Varret, B. SaintJore, D. Erlich, G. Jondeau, M. Krempf, P. Giraudet, C. Junien, and C. Boileau. 1997. Familial ligand-defective apolipoprotein B-100: simultaneous detection of the Arg(3500)→Gln and Arg(3531)→Cys mutations in a French population. Hum. Mutat. 10: 160-163.
32. Myant, N. B. 1993. Familial defective apolipoprotein B-100 - a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis. 104: 1-18.
33. Hansen, P. S., J. C. Defesche, J. J. P. Kastelein, L. U. Gerdes, L. Fraza, C. Gerdes, F. Tato, H. K. Jensen, L. G. Jensen, I. C. Klausen, O. Kaergeman, and H. Schuster. 1997. Phenotypic variation in patients heterozygous for familial defective apolipoprotein B (FDB) in three European countries. Arterioscler. Thromb. Vasc. Biol. 17: 741-747.
34. Miserez, A. R., and U. Keller. 1995. Differences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 15: 1719-1729.
35. Dunning, A. M., H-H. Renges, C-F. Xu, R. Peacock, R. Brasseur, G. Laxer, M. J. Tikkanen, R. Bütler, N. Saha, A. Hamsten, M. Rosseneu, P. Talmud, and S. E. Humphries. 1992. Two amino acid substitutions in apolipoprotein B are in complete allelic association with the antigen group (x/y) polymorphism: evidence for little recombination in the 3′ end of the human gene. Am. J. Hum. Genet. 50: 208-221.
36. Ludwig, E. H., and B. J. McCarthy. 1990. Haplotype analysis of the human apolipoprotein B mutation associated with familial defective apolipoprotein B-100. Am. J. Hum. Genet. 47: 712-720.
37. Rauh, G., H. Schuster, J. Fischer, C. Keller, G. Wolfram, and N. Zollner. 1991. Familial defective apolipoprotein B-100:haplotype analysis of the arginine 3500-glutamine mutation. Atherosclerosis. 88: 219-226.
38. Rauh, G., H. Schuster, C. K. Schewe, G. Stratmann, C. Keller, G. Wolfram, and N. Zollner. 1993. Independent mutation of arginine(3500)→glutamine associated with familial defective apolipoprotein B-100. J. Lipid Res. 34: 799-805.
39. Bersot, T. P., S. J. Russell, S. R. Thatcher, N. K. Pomernacki, R. W. Mahley, K. H. Weisgraber, T. L. Innerarity, and C. S. Fox. 1993. A unique haplotype of the apolipoprotein B-100 allele associated with familial defective apolipoprotein B-100 in a Chinese man discovered during a study of the prevalence of this disorder. J. Lipid Res. 34: 1149-1154.
40. Choong, M. L., E. S. C. Koay, K. L. Khoo, M. C. Khaw, and S. K. Sethi. 1997. Denaturing gradient-gel electrophoresis screening of familiar defective apolipoprotein B-100 in a mixed Asian cohort: two cases of arginine (3500)→tryptophan mutation associated with a unique haplotype. Clin. Chem. 43: 916-923.
41. Tybjærg-Hansen, A., R. Steffensen, H. Meinertz, P. Schnohr, and B. G. Nordestgaard. 1998. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N. Engl. J. Med. 338: 1577-1584.